A High-Profile Break Up
Executive Summary
The termination of PE Biosystem Group's acquisition of Third Wave Technologies has sprouted a number of unfounded rumors. But the reason seems to be what the companies initially said it was: A Department of Justice review of the merger for antitrust violations was taking longer than expected. With no end in sight to it and an uncertain outcome, the companies were losing business opportunities in a fast-moving field. Rather, they decided to continue to work together in an alliance, and have already established a joint venture that is one of the world's largest production facilities of oligonucleotides.
You may also be interested in...
Your Friend, the FTC: Nastech Solves a Knotty Anti-Trust Problem
When the FTC forced Pfizer/Pharmacia to divest Nastech's nasal apomorphine--a potential competitor of Pfizer's Viagra--Nastech managed what may be a unique solution: it got the product back, with additional financing-and in so doing, solved the very different problems of Pharmacia, Pfizer, the FTC, and itself.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.